KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accumulated Expenses: 2018-2024

Historic Accumulated Expenses for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $32.6 million.

  • Castle Biosciences' Accumulated Expenses rose 14.78% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 14.78%. This contributed to the annual value of $32.6 million for FY2024, which is 12.47% up from last year.
  • Castle Biosciences' Accumulated Expenses amounted to $32.6 million in FY2024, which was up 12.47% from $28.9 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Accumulated Expenses peaked at $32.6 million during FY2024, and registered a low of $9.1 million during FY2020.
  • Over the past 3 years, Castle Biosciences' median Accumulated Expenses value was $28.9 million (recorded in 2023), while the average stood at $28.6 million.
  • Data for Castle Biosciences' Accumulated Expenses shows a peak YoY surged of 69.99% (in 2021) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Accumulated Expenses (Yearly) stood at $9.1 million in 2020, then skyrocketed by 69.99% to $15.5 million in 2021, then surged by 57.32% to $24.4 million in 2022, then rose by 18.83% to $28.9 million in 2023, then climbed by 12.47% to $32.6 million in 2024.